Literature DB >> 15102312

Chemotherapy-evoked painful peripheral neuropathy.

R C Polomano1, G J Bennett.   

Abstract

Vincristine and paclitaxel, two of the most effective drugs in the battle against cancer, produce a dose-limiting neurotoxicity that sometimes presents as a painful peripheral neuropathy. For the first time, investigators have been able to produce these chemotherapy-evoked painful peripheral neuropathies in the laboratory rat. These new models have already begun to elucidate the causes of the neuropathic pain associated with these antineoplastic drugs, which will now make it possible to search for effective ways to prevent and treat it.

Entities:  

Year:  2001        PMID: 15102312     DOI: 10.1046/j.1526-4637.2001.002001008.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  45 in total

1.  Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.

Authors:  Laurence Meyer; Christine Patte-Mensah; Omar Taleb; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2010-04-30       Impact factor: 9.261

2.  Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.

Authors:  Caraceni Augusto; Miccoli Pietro; Martini Cinzia; Curzi Sergio; Cresta Sara; Gianni Luca; Vidmer Scaioli
Journal:  J Neurooncol       Date:  2007-07-05       Impact factor: 4.130

3.  Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats.

Authors:  Elzbieta P Wala; Peter A Crooks; J Michael McIntosh; Joseph R Holtman
Journal:  Anesth Analg       Date:  2012-05-18       Impact factor: 5.108

4.  Role of Drp1, a key mitochondrial fission protein, in neuropathic pain.

Authors:  Luiz F Ferrari; Adrienne Chum; Oliver Bogen; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2011-08-03       Impact factor: 6.167

5.  Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord.

Authors:  Jing-Dun Xie; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  Neuropharmacology       Date:  2017-06-27       Impact factor: 5.250

6.  Increased spinal cord Na⁺-K⁺-2Cl⁻ cotransporter-1 (NKCC1) activity contributes to impairment of synaptic inhibition in paclitaxel-induced neuropathic pain.

Authors:  Shao-Rui Chen; Lihong Zhu; Hong Chen; Lei Wen; Geoffroy Laumet; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2014-09-24       Impact factor: 5.157

7.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 8.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

9.  Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.

Authors:  Elizabeth J Rahn; Alexander M Zvonok; Ganesh A Thakur; Atmaram D Khanolkar; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

Review 10.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.